OTC · CIK 0001742927
RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC.
Insider trading from SEC Form 4. Last filing Mar 20, 2026.
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) has 11 SEC Form 4 filings on file from 6 insiders, the latest filed on Mar 20, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at REVIVA PHARMACEUTICALS HOLDINGS, INC., scored.
Transactions
Every row filed, 13 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | Laxminarayan Bhat President and CEO | AGrant or award Stock Option (right to buy)derivative | +109,150 | $0.00 | $0 | 109,150 | Mar 20, 2026 |
| Mar 18, 2026 | Narayan Prabhu Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +40,925 | $0.00 | $0 | 40,925 | Mar 20, 2026 |
| Mar 18, 2026 | Laxminarayan Bhat President and CEO | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +40,925 | $0.00 | $0 | 40,925 | Mar 20, 2026 |
| Dec 18, 2025 | Leslie D. Funtleyder director | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 19, 2025 |
| Dec 18, 2025 | Richard A Margolin director | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 19, 2025 |
| Dec 18, 2025 | Purav Patel director | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 19, 2025 |
| Dec 18, 2025 | Parag Saxena director | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 19, 2025 |
| Feb 13, 2025 | Laxminarayan Bhat President and CEO | AGrant or award Stock Option (right to buy)derivative | +519,000 | $0.00 | $0 | 519,000 | Feb 18, 2025 |
| Feb 13, 2025 | Laxminarayan Bhat President and CEO | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +181,500 | $0.00 | $0 | 181,500 | Feb 18, 2025 |
| Dec 10, 2024 | Leslie D. Funtleyder director | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 12, 2024 |
| Dec 10, 2024 | Richard A Margolin director | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 12, 2024 |
| Dec 10, 2024 | Purav Patel director | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 12, 2024 |
| Dec 10, 2024 | Parag Saxena director, owner | AGrant or award Stock Option (right to buy)derivative | +8,200 | $0.00 | $0 | 8,200 | Dec 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Laxminarayan BhatPresident and CEO
- Leslie D. Funtleyderofficer, director, cfo
- Richard A Margolindirector
- Purav Pateldirector
- Narayan PrabhuChief Financial Officer
- Parag Saxenadirector, owner
Questions about RVPH
Answered from the filings on this page, as of the latest one.
Are insiders buying RVPH?
No. In the last 90 days no insider at REVIVA PHARMACEUTICALS HOLDINGS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RVPH on the open market?
No open-market trade has been scored at REVIVA PHARMACEUTICALS HOLDINGS, INC.. The latest Form 4 on file was filed on Mar 20, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at REVIVA PHARMACEUTICALS HOLDINGS, INC.?
6 people have filed a Form 4 at REVIVA PHARMACEUTICALS HOLDINGS, INC., among them Laxminarayan Bhat (President and CEO), Leslie D. Funtleyder (director and CFO), Richard A Margolin (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.